Breast cancer risk 2008: Obsessing

March 18, 2008

How many breast cancer patients (and MDs) ignore the greater risks?

The odds are about 50:50 that a breast cancer survivor over 60 will die as a result of something else – most likely heart disease or osteoporosis – according to a new report in the Journal of the National Cancer Institute. It calls for greater attention to these women’s other medical problems.

Another study in the same issue finds that women diagnosed with ductal carcinoma in situ (DCIS) radically overestimated their risk of progression to cancer or metastasis. They also showed “notable declines” in general health, vitality, and mental health during the 18 months after diagnosis.

A companion editorial to this study (look for the link at the bottom of the abstract) tentatively suggests a trial of “watchful waiting” for DCIS—rather than knee-jerk mastectomy. If it works for prostate cancer, then why not for this pre-malignant condition?

These articles aren’t full of advice about how to help patients who fret about their condition. But there are ideas elsewhere on SearchMedica.

Clinical Trials

Find the new trial mentioned in the DCIS editorial that is testing brief hormonal therapy before surgery. Researchers are looking for changes in tumor volume, with a goal of finding nonsurgical means to avert progression.

Patient Education

Find something worth sending home with a patient who will be thinking a long time about her diagnosis of early breast cancer.


Thinking more clearly about cognition

March 3, 2008

MATRICS project heralds new era in cognitive improvement

Newly published results of the massive MATRICS project from the NIMH are already beginning to rationalize research toward new drug treatments for cognitive deficits in schizophrenia. What are the progress and prospects that result from this collaborative effort?

It won’t just be schizophrenia. The battery of 10 standard tests also have implications for future studies of cognitive impairment in affective disorders—and its relation to functional outcomes.

Clinical Trials
Clinical trials now underway are using or testing the MATRICS battery.

Practical Articles/News
Radically new drug developments are using MATRICS battery to establish effects on cognition as well as social function and other outcomes.

(One author appeals to clinicians to use these same tests to monitor the success of their treatments for schizophrenia.)